- Home
- NIVF vs ALZN Comparison
NIVF vs ALZN Comparison
Compare NIVF & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIVF
- ALZN
- Stock Information
- Founded
- NIVF 2011
- ALZN 2016
- Country
- NIVF Thailand
- ALZN United States
- Employees
- NIVF N/A
- ALZN N/A
- Industry
- NIVF
- ALZN Medicinal Chemicals and Botanical Products
- Sector
- NIVF
- ALZN Health Care
- Exchange
- NIVF NYSE
- ALZN Nasdaq
- Market Cap
- NIVF 2.1M
- ALZN 2.3M
- IPO Year
- NIVF N/A
- ALZN 2021
- Fundamental
- Price
- NIVF $0.62
- ALZN $3.20
- Analyst Decision
- NIVF
- ALZN Strong Buy
- Analyst Count
- NIVF 0
- ALZN 1
- Target Price
- NIVF N/A
- ALZN $180.00
- AVG Volume (30 Days)
- NIVF 3.8M
- ALZN 429.8K
- Earning Date
- NIVF 01-01-0001
- ALZN 09-10-2025
- Dividend Yield
- NIVF N/A
- ALZN N/A
- EPS Growth
- NIVF N/A
- ALZN N/A
- EPS
- NIVF N/A
- ALZN N/A
- Revenue
- NIVF $5,433,375.00
- ALZN N/A
- Revenue This Year
- NIVF N/A
- ALZN $322.64
- Revenue Next Year
- NIVF N/A
- ALZN N/A
- P/E Ratio
- NIVF N/A
- ALZN N/A
- Revenue Growth
- NIVF 5.79
- ALZN N/A
- 52 Week Low
- NIVF $0.61
- ALZN $2.75
- 52 Week High
- NIVF $656.00
- ALZN $135.54
- Technical
- Relative Strength Index (RSI)
- NIVF 27.45
- ALZN 47.56
- Support Level
- NIVF $0.61
- ALZN $2.81
- Resistance Level
- NIVF $1.24
- ALZN $3.05
- Average True Range (ATR)
- NIVF 0.12
- ALZN 0.17
- MACD
- NIVF 0.03
- ALZN 0.09
- Stochastic Oscillator
- NIVF 2.36
- ALZN 75.01
About NIVF NEWGENIVF GROUP LIMITED
NewGenIvf Group Ltd is a company engaged in providing assisted reproductive services in Asia Pacific with a focus on providing fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely first which is a in-vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and surrogacy and ancillary caring services.
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.